Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism
This study is conducted to assess the efficacy and safety of SK-1403 in Hemodialysis Patients with Secondary Hyperparathyroidism. In the first treatment period, the efficacy of SK-1403 is assessed after 18 weeks of treatment with SK-1403 individually dose-adjusted . Safety is also assessed during this period. Patients who completed the first treatment period proceed to the second treatment period and receive the treatment with SK-1403 for 34 weeks. Efficacy and safety of SK-1403 are also assessed during this period.
Secondary Hyperparathyroidism
DRUG: Dose-adjusted SK-1403
Rate of patients who achieved serum PTH between 60 pg/mL and 240 pg/mL, inclusive, Assessed by laboratory test value, 18 weeks
Rate of patients who achieved â‰¥ 30% or 50% reduction in serum PTH from baseline, respectively, Assessed by laboratory test value, 18 weeks|Measured values and Changes from baseline in serum PTH, Ca, P, and serum Ca x P product, Assessed by laboratory test value, 52 weeks
This study is conducted to assess the efficacy and safety of SK-1403 in Hemodialysis Patients with Secondary Hyperparathyroidism. In the first treatment period, the efficacy of SK-1403 is assessed after 18 weeks of treatment with SK-1403 individually dose-adjusted . Safety is also assessed during this period. Patients who completed the first treatment period proceed to the second treatment period and receive the treatment with SK-1403 for 34 weeks. Efficacy and safety of SK-1403 are also assessed during this period.